title: [Cutting-edge of medicine; the prospects of novel anti-obesity drugs].
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Ueno
authors.forename: Masamitsu
authors.initials: M
authors.lastname: Nakazato
mesh_terms: D019440:Anti-Obesity Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D001066:Appetite / Q000187:drug effects; D001067:Appetite Depressants; D001552:Benzazepines; D048588:Benzoxazines; D016642:Bupropion; D002986:Clinical Trials as Topic; D017277:Drug Approval; D004338:Drug Combinations; D055808:Drug Discovery / Q000639:trends*; D004734:Energy Metabolism / Q000187:drug effects; D004791:Enzyme Inhibitors; D005632:Fructose / Q000031:analogs & derivatives; D052216:Glucagon-Like Peptide 1 / Q000819:agonists / Q000031:analogs & derivatives; D006801:Humans; D007031:Hypothalamus / Q000502:physiology; D007783:Lactones; D008049:Lipase / Q000037:antagonists & inhibitors; D000069450:Liraglutide; D024821:Metabolic Syndrome / Q000209:etiology; D009271:Naltrexone; D009765:Obesity / Q000150:complications / Q000188:drug therapy*; D000077403:Orlistat; D010645:Phentermine; D000077236:Topiramate
chemical_list: D019440:Anti-Obesity Agents; D001067:Appetite Depressants; D001552:Benzazepines; D048588:Benzoxazines; D004338:Drug Combinations; D004791:Enzyme Inhibitors; D007783:Lactones; C576188:Qsymia; C000591595:bupropion hydrochloride, naltrexone hydrochoride drug combination; D016642:Bupropion; D000077236:Topiramate; D005632:Fructose; D009271:Naltrexone; C506658:lorcaserin; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1; D000077403:Orlistat; D010645:Phentermine; D008049:Lipase; C520092:cetilistat